Tina M. Albertson net worth and biography

Tina Albertson Biography and Net Worth

Insider of Caribou Biosciences

Tina is the chief medical officer for Caribou Biosciences and is responsible for strategic leadership of the company’s clinical programs and the clinical, regulatory, and medical affairs functions. Tina brings 15 years of experience leading the development of cellular therapies and biologics. Previously, Tina was chief medical officer and head of development for Lyell Immunopharma, where she built and led the clinical development function and initiated two Phase 1 clinical trials evaluating CAR-T cell and TIL therapies in solid tumors. Prior to Lyell, she was vice president of global drug development at Juno Therapeutics, where she led the global development of BREYANZI (lisocabtagene maraleucel) from preclinical studies to the BLA filing that ultimately led to the initial FDA approval. She previously served as medical director of clinical development and experimental medicine at Seagen (formerly Seattle Genetics). Tina earned her MD from Stanford University and completed a clinical fellowship in pediatric hematology/oncology at Seattle Children’s Hospital and residency in pediatrics at Denver Children’s Hospital. She earned her PhD in cancer biology from the University of Washington and her BS in molecular biology from the University of Oregon.

What is Tina M. Albertson's net worth?: The estimated net worth of Tina M. Albertson is at least $109.98 thousand as of February 24th, 2026. Albertson owns 68,523 shares of Caribou Biosciences stock worth more than $109,979 as of August 6th. This net worth approximation does not reflect any other assets that Albertson may own. Learn More about Tina M. Albertson's net worth.
How do I contact Tina M. Albertson?: The corporate mailing address for Albertson and other Caribou Biosciences executives is , , . Caribou Biosciences can also be reached via phone at 510-982-6030 and via email at [email protected]. Learn More on Tina M. Albertson's contact information.
Has Tina M. Albertson been buying or selling shares of Caribou Biosciences?: Tina M. Albertson has not been actively trading shares of Caribou Biosciences over the course of the past ninety days. Most recently, Tina M. Albertson sold 1,066 shares of the business's stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $1.96, for a transaction totalling $2,089.36. Following the completion of the sale, the insider now directly owns 68,523 shares of the company's stock, valued at $134,305.08. Learn More on Tina M. Albertson's trading history.
Who are Caribou Biosciences' active insiders?: Caribou Biosciences' insider roster includes Tina Albertson (Insider), Ryan Fischesser (VP), Rachel Haurwitz (Co-Founder), Rachel Haurwitz (CEO), Steven Kanner (Insider), Timothy Kelly (CTO), Ruhi Khan (Insider), Barbara McClung (Insider), and Sriram Ryali (CFO). Learn More on Caribou Biosciences' active insiders.
Are insiders buying or selling shares of Caribou Biosciences?: During the last year, insiders at the sold shares 4 times. They sold a total of 18,089 shares worth more than $35,454.44. The most recent insider tranaction occured on February, 24th when CTO Timothy P Kelly sold 3,147 shares worth more than $6,168.12. Insiders at Caribou Biosciences own 8.5% of the company. Learn More about insider trades at Caribou Biosciences.
Information on this page was last updated on 2/24/2026.

Tina M. Albertson Insider Trading History at Caribou Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/24/2026	Sell	1,066	$1.96	$2,089.36	68,523

Tina M. Albertson Buying and Selling Activity at Caribou Biosciences

Caribou Biosciences Company Overview

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Today's Range

Now: $1.62

$1.59

$1.68

50 Day Range

MA: $1.76

$1.46

$2.43

2 Week Range

Now: $1.62

$1.38

$3.54

Volume

444,772 shs

Average Volume

1,579,234 shs

Market Capitalization

$160.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.38